TGFβ signaling is necessary for carcinoma cell invasiveness and metastasis

Current Biology

Volumn 8, Issue 23, 1998, Pages 1243-1252

  Oft, Martin ^a,b   Heider, Karl Heinz ^c   Beug, Hartmut ^a  

^a RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

^b ONYX PHARMACEUTICALS   (United States)

^c Bender Gmbh   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ANIMAL; ARTICLE; CANCER INVASION; CELL CULTURE; CELL CYCLE; COLON TUMOR; DRUG ANTAGONISM; EPITHELIUM CELL; HUMAN; MESODERM; METABOLISM; METASTASIS; MOUSE; MUTATION; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CELL CYCLE; COLONIC NEOPLASMS; EPITHELIAL CELLS; HUMANS; MESODERM; MICE; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 0032547895     PISSN: 09609822     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0960-9822(07)00533-7     Document Type: Article

References (45)

1. Kinzler KW, Vogelstein B: Lessons from hereditary colorectal cancer. Cell 1996, 87:159-170.
2. Nagase H, Bryson S, Fee F, Balmain A: Multigenic control of skin tumour development in mice. Ciba Found Symp 1996, 197:156-168; 168-180.
3. Liotta LA, Steeg PS, Stetler-Stevenson WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991, 64327-336.
4. Kimelman D, Kirschner M: Synergistic induction of mesoderm by FGF and TGF-beta and the identification of an mRNA coding for FGF in the early Xenopus embryo. Cell 1987, 51:869-877.
5. Sun D, Vanderburg CR, Odierna GS, Hay ED: TGFbeta3 promotes transformation of chicken palate medial edge epithelium to mesenchyme in vitro. Development 1998, 125:95-105.
6. Cui W, Fowlis DJ, Bryson S, Duffle E, Ireland H, Balmain A, et al.: TGFbeta1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 1996, 86:531-542.
7. Portella G, Gumming SA, Liddell J, Cui W, Ireland H, Akhurst RJ, et al.: Transforming growth factor beta is essential for spindle cell conversion of mouse skin carcinoma in vivo: implications for tumor invasion. Cell Growth Differ 1998, 9:393-404.
8. Derynck R, Feng XH : TGF-beta receptor signaling. Biochim Biophys Acta 1997, 1333:F105-F150.
9. Reynisdottir I, Polyak K, Iavarone A, Massague J: Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev 1995, 9:1831-1845.
10. Hannon GJ, Beach D: p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 1994, 371:257-261.
11. Maesawa C, Tamura G, Nishizuka S, Iwaya T, Ogasawara S, Ishida K, et al.: MAD-related genes on 18q21.1, Smad2 and Smad4, are altered infrequently in esophageal squamous cell carcinoma. Jpn J Cancer Res 1997, 88:340-343.
12. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, et al.: Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995, 268:1336-1338.
13. Schutte M, Hruban RH, Hedrick L, Cho KR, Nadasdy GM, Weinstein CL, et al.: DPC4 gene in various tumor types. Cancer Res 1996, 56:2527-2530.
14. Fynan TM, Reiss M: Resistance to inhibition of cell growth by transforming growth factor-beta and its role in oncogenesis. Crit Rev Oncog 1993, 4:493-540.
15. Dalal BI, Keown PA, Greenberg AH: Immunocytochemical localization of secreted transforming growth factor-beta 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma. Am J Pathol 1993, 143:381-389.
16. Sargent ER, Gomella LG, Wade TP, Ewing MW, Kasid A, Linehan WM: Expression of mRNA for transforming growth factors-alpha and -beta and secretion of transforming growth factor-beta by renal cell carcinoma cell lines. Cancer Commun 1989, 1:317-322.
17. Steiner MS, Zhou ZZ, Tonb DC, Barrack ER: Expression of transforming growth factor-beta 1 in prostate cancer. Endocrinology 1994, 135:2240-2247.
18. Walker RA, Dearing SJ, Gallacher B: Relationship of transforming growth factor beta 1 to extracellular matrix and stromal infiltrates in invasive breast carcinoma. Br J Cancer 1994, 69:1160-1165.
19. Galaktionov K, Lee AK, Eckstein J, Draetta G, Meckler J, Loda M, et al.: CDC25 phosphatases as potential human oncogenes. Science 1995, 269:1575-1577.
20. Iavarone A, Massague J: Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-beta in cells lacking the CDK inhibitor p15. Nature 1997, 387:417-422.
21. Tang B, Bottinger EP, Jakowlew SB, Bagnall KM, Mariano J, Anver MR, et al.: Transforming growth factor-beta1 is a new form of tumor suppressor with true haploid insufficiency. Nat Med 1998, 4:802-807.
22. Kehrl JH, Roberts AB, Wakefield LM, Jakowlew S, Sporn MB, Fauci AS: Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes. J Immunol 1986, 137:3855-3860.
23. Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, et al.: Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 1986, 83:4167-4171.
24. Zambruno G, Marchisio PC, Marconi A, Vaschieri C, Melchiori A, Giannetti A, et al.: Transforming growth factor-beta 1 modulates beta 1 and beta 5 integrin receptors and induces the de novo expression of the alpha v beta 6 heterodimer in normal human keratinocytes: implications for wound healing. J Cell Biol 1995, 129:853-865.
25. Oft M, Peli J, Rudaz C, Schwarz H, Beug H, Reichmann E: TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev 1996, 10:2462-2477.
26. Lin HY, Wang XF, Ng-Eaton E, Weinberg RA, Lodish HF: Expression cloning of the TGF-beta type II receptor, a functional transmembrane serine/threonine kinase. Cell 1992, 68:775-785.
27. Wrana JL, Attisano L, Wieser R, Ventura F, Massague J: Mechanism of activation of the TGF-beta receptor. Nature 1994, 370:341 -347.
28. Wrana JL, Attisano L, Carcamo J, Zentella A, Doody J, Laiho M, et al.: TGF beta signals through a heteromeric protein kinase receptor complex. Cell 1992, 71:1003-1014.
29. Brattain MG, Strobel-Stevens J, Fine D, Webb M, Sarrif AM: Establishment of mouse colonic carcinoma cell lines with different metastatic properties. Cancer Res 1980, 40:2142-2146.
30. Corbett TH, Griswold DPJ, Roberts BJ, Peckham JC, Schabel FMJ: Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res 1975, 352434-2439.
31. Chang J, Park K, Bang YJ, Kim WS, Kim D, Kim SJ: Expression of transforming growth factor beta type II receptor reduces tumorigenicity in human gastric cancer cells. Cancer Res 1997, 57:2856-2859.
32. Thompson TC, Truong LD, Timme TL, Kadmon D, McCune BK, Flanders KC, et al.: Transforming growth factor beta 1 as a biomarker for prostate cancer. J Cell Biochem Suppl 1992, 16H:54-61.
33. Thompson TC, Truong LD, Timme TL, Kadmon D, McCune BK, Flanders KC, et al.: Transgenic models for the study of prostate cancer. Cancer 1993, 71:1165-1171.
34. Sehgal I, Baley PA, Thompson TC: Transforming growth factor betal stimulates contrasting responses in metastatic versus primary mouse prostate cancer-derived cell lines in vitro. Cancer Res 1996, 56:3359-3365.
35. Rashid A, Hamilton SR: Genetic alterations in sporadic and Crohn's-associated adenocarcinomas of the small intestine. Gastroenterology 1997, 113:127-135.
36. Takenoshita S, Hagiwara K, Gemma A, Nagashima M, Ryberg D, Lindstedt BA, et al.: Absence of mutations in the transforming growth factor-beta type II receptor in sporadic lung cancers with microsatellite instability and rare H-ras1 alleles. Carcinogenesis 1997, 18:1427-1429.
37. Lei J, Zou TT, Shi YQ, Zhou X, Smolinski KN, Yin J, et al.: Infrequent DPC4 gene mutation in esophageal cancer, gastric cancer and ulcerative colitis-associated neoplasms. Oncogene 1996, 13:2459-2462.
38. Kim SK, Fan Y, Papadimitrakopoulou V, Clayman G, Hittelman WN, Hong WK, et al.: DPC4, a candidate tumor suppressor gene, is altered infrequently in head and neck squamous cell carcinoma. Cancer Res 1996, 562519-2521.
39. Nagatake M, Takagi Y, Osada H, Uchida K, Mitsudomi T, Saji S, et al.: Somatic in vivo alterations of the DPC4 gene at 18q21 in human lung cancers. Cancer Res 1996, 56:2718-2720.
40. NishizukaS, Tamura G, Maesawa C, Sakata K, Suzuki Y, Iwaya T, et al.: Analysis of the DPC4 gene in gastric carcinoma. Jpn J Cancer Res 1997, 88:335-339.
41. Riggins GJ, Kinzler KW, Vogelstein B, Thiagalingam S: Frequency of Smad gene mutations in human cancers. Cancer Res 1997, 57:2578-2580.
42. Takagi Y, Kohmura H, Futamura M, Kida H, Tanemura H, Shimokawa K, et al.: Somatic alterations of the DPC4 gene in human colorectal cancers in vivo. Gastroenterology 1996, 111:1369-1372.
43. Derynck R, Jarrett JA, Chen EY, Eaton DH, Bell JR, Assoian RK, et al.: Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. Nature 1985, 316:701-705.
44. Morgenstern JP, Land H: Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res 1990, 183587-3596.
45. Pear WS, Nolan GP, Scott ML, Baltimore D: Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 1993, 15:8392-8396.